{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:54:15Z","timestamp":1787756055414,"version":"build-2784847793"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Almirall S.A."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s13555-016-0161-2","type":"journal-article","created":{"date-parts":[[2016,12,19]],"date-time":"2016-12-19T12:26:28Z","timestamp":1482150388000},"page":"81-96","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Efficacy and Safety of 5-Fluorouracil 0.5%\/Salicylic Acid 10% in the Field-Directed Treatment of Actinic Keratosis: A Phase III, Randomized, Double-Blind, Vehicle-Controlled Trial"],"prefix":"10.1007","volume":"7","author":[{"given":"Eggert","family":"Stockfleth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"von Kiedrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Dominicus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Ellery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meritxell","family":"Falqu\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Ivanoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario Rodriguez","family":"Azeredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,19]]},"reference":[{"key":"161_CR1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1684\/ejd.2014.2286","volume":"24","author":"M Ulrich","year":"2014","unstructured":"Ulrich M, Pellacani G, Ferrandiz C, Lear JT. Evidence for field cancerisation treatment of actinic keratoses with topical diclofenac in hyaluronic acid. Eur J Dermatol. 2014;24:158\u201367.","journal-title":"Eur J Dermatol."},{"key":"161_CR2","doi-asserted-by":"crossref","first-page":"456071","DOI":"10.1155\/2015\/456071","volume":"2015","author":"JS Kirby","year":"2015","unstructured":"Kirby JS, Scharnitz T, Seiverling EV, Ahrns H, Ferguson S. Actinic keratosis clinical practice guidelines: an appraisal of quality. Dermatol Res Pract. 2015;2015:456071.","journal-title":"Dermatol Res Pract."},{"key":"161_CR3","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/jdv.12848","volume":"29","author":"MT Fern\u00e1ndez-Figueras","year":"2015","unstructured":"Fern\u00e1ndez-Figueras MT, Carrato C, S\u00e1enz X, et al. Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin. J Eur Acad Dermatol Venereol. 2015;29:991\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"161_CR4","first-page":"1462","volume":"11","author":"E Stockfleth","year":"2012","unstructured":"Stockfleth E. The paradigm shift in treating actinic keratosis: a comprehensive strategy. J Drugs Dermatol. 2012;11:1462\u20137.","journal-title":"J Drugs Dermatol"},{"issue":"1 Suppl 1","key":"161_CR5","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jaad.2012.09.052","volume":"68","author":"T Rosen","year":"2013","unstructured":"Rosen T, Lebwohl MG. Prevalence and awareness of actinic keratosis: barriers and opportunities. J Am Acad Dermatol. 2013;68(1 Suppl 1):S2\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"161_CR6","doi-asserted-by":"crossref","unstructured":"Gupta AK, Paquet M, Villanueva E, Brintnell W. Interventions for actinic keratoses. Cochrane Database Syst Rev. 2012;12:CD004415.","DOI":"10.1002\/14651858.CD004415.pub2"},{"issue":"1","key":"161_CR7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1684\/ejd.2013.1923","volume":"23","author":"D Nashan","year":"2013","unstructured":"Nashan D, Meiss F, Muller M. Therapeutic strategies for actinic keratoses\u2013a systematic review. Eur J Dermatol. 2013;23(1):14\u201332.","journal-title":"Eur J Dermatol."},{"key":"161_CR8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/CIA.S31930","volume":"8","author":"EE Uhlenhake","year":"2013","unstructured":"Uhlenhake EE. Optimal treatment of actinic keratoses. Clin Interv Aging. 2013;8:29\u201335.","journal-title":"Clin Interv Aging"},{"key":"161_CR9","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1111\/jdv.13180","volume":"29","author":"RN Werner","year":"2015","unstructured":"Werner RN, Stockfleth E, Connolly SM, et al. Evidence- and consensus-based (S3) guidelines for the treatment of actinic keratosis\u2014international league of dermatological societies in cooperation with the European Dermatology Forum - Short version. J Eur Acad Dermatol Venereol. 2015;29:2069\u201379.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"161_CR10","unstructured":"Bower C, Keohane S, Kownacki S, et al. Primary care dermatology society clinical guidance. Actinic (solar) keratosis\u2014primary care treatment pathway. http:\/\/www.pcds.org.uk\/a-z-clinical-guidance\/clinical-a-z-list . Accessed July 20, 2016."},{"key":"161_CR11","first-page":"651","volume":"18","author":"E Stockfleth","year":"2008","unstructured":"Stockfleth E, Ferrandiz C, Grob JJ, Leigh I, Pehamberger H, Kerl H. Development of a treatment algorithm for actinic keratoses: a European consensus. Eur J Dermatol. 2008;18:651\u20139.","journal-title":"Eur J Dermatol."},{"key":"161_CR12","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/0190-9622(91)70113-G","volume":"24","author":"EA Olsen","year":"1991","unstructured":"Olsen EA, Abernethy ML, Kulp-Shorten C, et al. A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol. 1991;24:738\u201343.","journal-title":"J Am Acad Dermatol"},{"key":"161_CR13","unstructured":"Actikerall summary of product characteristics. www.medicines.org.uk\/emc\/medicine\/24614\/SPC\/Actikerall+5mg+g+%2B+100mg+g+Cutaneous+Solution\/ . Accessed July 20, 2016."},{"issue":"1","key":"161_CR14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s13555-015-0070-9","volume":"5","author":"P Chetty","year":"2015","unstructured":"Chetty P, Choi F, Mitchell T. Primary care review of actinic keratosis and its therapeutic options: a global perspective. Dermatol Ther (Heidelb). 2015;5(1):19\u201335.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"161_CR15","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/j.1365-2133.2011.10387.x","volume":"165","author":"E Stockfleth","year":"2011","unstructured":"Stockfleth E, Kerl H, Zwingers T, Willers C. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol. 2011;165:1101\u20138.","journal-title":"Br J Dermatol"},{"key":"161_CR16","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1684\/ejd.2012.1707","volume":"22","author":"E Stockfleth","year":"2012","unstructured":"Stockfleth E, Zwingers T, Willers C. Recurrence rates and patient assessed outcomes of 0.5% 5-fluorouracil in combination with salicylic acid treating actinic keratoses. Eur J Dermatol. 2012;22:370\u20134.","journal-title":"Eur J Dermatol."},{"key":"161_CR17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2340\/00015555-2167","volume":"96","author":"E Stockfleth","year":"2016","unstructured":"Stockfleth E, Sibbring GC, Alarcon I. New topical treatment options for actinic keratosis: a systematic review. Acta Derm Venereol. 2016;96:17\u201322.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"161_CR18","first-page":"335","volume":"16","author":"PJ Quaedvlieg","year":"2006","unstructured":"Quaedvlieg PJ, Tirsi E, Thissen MR, Krekels GA. Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol. 2006;16(4):335\u20139.","journal-title":"Eur J Dermatol."},{"issue":"3 Pt 1","key":"161_CR19","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0190-9622(97)70137-3","volume":"37","author":"JM Suchniak","year":"1997","unstructured":"Suchniak JM, Baer S, Goldberg LH. High rate of malignant transformation in hyperkeratotic actinic keratoses. J Am Acad Dermatol. 1997;37(3 Pt 1):392\u20134.","journal-title":"J Am Acad Dermatol"},{"key":"161_CR20","first-page":"430","volume":"13","author":"RM Szeimies","year":"2015","unstructured":"Szeimies RM, Dirschka T, Prechtl A, Melzer A. Efficacy of low-dose 5-fluorouracil\/salicylic acid in actinic keratoses in relation to treatment duration. J Dtsch Dermatol Ges. 2015;13:430\u20138.","journal-title":"J Dtsch Dermatol Ges."},{"key":"161_CR21","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000370148","volume":"230","author":"M Ulrich","year":"2015","unstructured":"Ulrich M, Alarcon I, Malvehy J, Puig S. In vivo reflectance confocal microscopy characterization of field-directed 5-fluorouracil 0.5%\/salicylic acid 10% in actinic keratosis. Dermatology. 2015;230:193\u20138.","journal-title":"Dermatology"},{"key":"161_CR22","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/jdv.13445","volume":"30","author":"J Malvehy","year":"2016","unstructured":"Malvehy J, Alarcon I, Montoya J, Rodriguez-Azeredo R, Puig S. Treatment monitoring of 0.5% 5-fluorouracil and 10% salicylic acid in clinical and subclinical actinic keratoses with the combination of optical coherence tomography and reflectance confocal microscopy. J Eur Acad Dermatol Venereol. 2016;30:258\u201365.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"161_CR23","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jaad.2009.06.020","volume":"62","author":"CW Hanke","year":"2010","unstructured":"Hanke CW, Beer KR, Stockfleth E, Wu J, Rosen T, Levy S. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. J Am Acad Dermatol. 2010;62:573\u201381.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"161_CR24","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1517\/14740338.2015.1108962","volume":"14","author":"B Berman","year":"2015","unstructured":"Berman B. Safety and tolerability of ingenol mebutate in the treatment of actinic keratosis. Expert Opin Drug Saf. 2015;14(12):1969\u201378.","journal-title":"Expert Opin Drug Saf."},{"key":"161_CR25","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ad.2011.10.017","volume":"103","author":"M Ulrich","year":"2012","unstructured":"Ulrich M, Lange-Asschenfeldt S, Gonzalez S. In vivo reflectance confocal microscopy for early diagnosis of nonmelanoma skin cancer. Actas Dermosifiliogr. 2012;103:784\u20139.","journal-title":"Actas Dermosifiliogr."}],"updated-by":[{"DOI":"10.1007\/s13555-017-0179-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,4,18]],"date-time":"2017-04-18T00:00:00Z","timestamp":1492473600000}}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-016-0161-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T02:33:40Z","timestamp":1601260420000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13555-016-0161-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,19]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["161"],"URL":"https:\/\/doi.org\/10.1007\/s13555-016-0161-2","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s13555-017-0179-0","asserted-by":"object"}]},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,19]]}}}